Novo Nordisk Postdoctoral Research Fellow (2018)
- Project: Exploring a novel signalling in “dysfunctional” adipose tissue, mediating the cardiovascular complications of diabetes
Amy completed her Ph.D. training studying diabetic cardiovascular complications, from the perspective of metabolism, in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) in Canada.
She joined the Novo Nordisk Postdoctoral Research Programme in 2018, working with Professor Charalambos Antoniades and Professor Keith M Channon in the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford. Using a combination of in vitro and in vivo studies, the focus of her fellowship involved understanding the impact of dysfunctional adipose tissue mediating the cardiovascular complications of diabetes. After her Novo Nordisk fellowship, she has been involved in the family business and licensing digital healthcare solutions in consumable smartwatches.
Adipose tissue–derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases. Akoumianakis I et al, (2019) Sci Transl Med